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This study aimed to evaluate the prevalence of carbapenemase-producing Enterobacteriaceae in Luanda, Angola. A total of 157
rectal samples were collected from children visiting a pediatric hospital in Luanda in March 2015. Fifty-seven imipenem-nonsus-
ceptible enterobacterial isolates were recovered, most of which were non-clonally related. The blaOXA-181 (50/57) and blaNDM-1
(7/57) carbapenemase genes were identiﬁed. Notably, OXA-181-producing Escherichia coli isolates rarely coproduced extended-
spectrum-lactamases and consequently remained susceptible to broad-spectrum cephalosporins. The blaOXA-181 gene was al-
ways located on an IncX3 plasmid, while the blaNDM-1 gene was located on either IncFIA or IncA/C plasmids. The study identi-
ﬁed a high prevalence of OXA-181 among hospitalized children in Angola.
The increasing occurrence of carbapenem resistance in Gram-negative bacteria is one of the major public health problems
involving Enterobacteriaceae. Carbapenem resistance arises from
two main mechanisms: decreased uptake of carbapenems by
porins associated with overexpression of a -lactamase with weak
carbapenemase activity, and the acquisition of carbapenemases
(1). Carbapenemases belong to three different Ambler classes (2),
with class A including the serine carbapenemases KPC, NMC/
IMI, and SME; class B including the metallo--lactamases VIM,
IMP, and NDM; and class D including OXA-48-like -lactamases
(OXA-48,OXA-181, etc.). Since the initial report ofOXA-48 from
a Klebsiella pneumoniae isolate in 2003 (3), OXA-48-like enzymes
have been recovered in a variety of Enterobacteriaceae worldwide,
particularly within the Mediterranean area, including southern
Europe and northern Africa, but also in the Middle East (4). Vari-
ants of OXA-48 have been described (5), including OXA-181,
which differs from OXA-48 by 4 amino acids while sharing a very
similar hydrolytic proﬁle (6). Bacteria producing OXA-48-like
-lactamases do not always exhibit high levels of resistance to
carbapenems, making their detection challenging (4). The epide-
miology of carbapenemases in Africa remains mostly unknown,
with the exception of OXA-48, which was identiﬁed in the north-
ern part of the continent (Algeria, Egypt, Morocco, and Tunisia)
(4, 7), and some reports of KPC- and NDM-like enzymes in South
Africa (7). However, there are limited data about the occurrence
of carbapenemase producers in most of the other African coun-
tries. Therefore, we investigated the occurrence and molecular
characteristics of carbapenemase-producing enterobacterial iso-
lates recovered from rectal samples from children visiting a pedi-
atric hospital in Luanda, Angola.
MATERIALS AND METHODS
Bacterial isolates and susceptibility testing. A total of 157 rectal swabs
were collected on 30 and 31 March 2015 from hospitalized patients (n
100) and from ambulatory patients (n 57). The samples were incubated
in Luria-Bertani (LB) broth supplemented with ertapenem (0.25g/ml) for
10 h. From each broth, a calibrated inoculated loop (10 l) was plated onto
ChromID CarbaSmart selective medium (bioMérieux, La Balme-les-
Grottes, France) to select for carbapenem-resistant isolates. The
isolates were identiﬁed at the species level using the API20E system
(bioMérieux). Antimicrobial susceptibility testing was performed ac-
cording to the disc diffusion method following the CLSI recommen-
dations (8) and using cation-adjusted Mueller-Hinton (MH) plates
(Bio-Rad, Cressier, Switzerland).
MICs were determined by Etest (bioMérieux, La Balme-les-Grottes,
France) for imipenem, meropenem, and ceftazidime. Carbapenemase
activity was assessed using the RapidecCarbaNP test (9) (bioMérieux) for
each isolate growing on the ChromID CarbaSmart plate.
Molecular analysis. Carbapenemase- and extended-spectrum -lac-
tamase (ESBL)-encoding genes were identiﬁed by PCR ampliﬁcation us-
ing speciﬁc primers as described previously (10–12), followed by sequenc-
ing (Microsynth, Balgach, Switzerland).
Considering the high-level resistance to all aminoglycosides observed
for some isolates, a search of 16S rRNA methylase-encoding genes was
performed by multiplex PCR as described previously (13). Similarly, a
search of plasmid-mediated Qnr-like encoding genes involved in reduced
susceptibility to quinolones was performed by multiplex PCR, as de-
scribed previously (14). Finally, a search of the plasmid-mediated colistin
resistance mcr-1 gene was performed by real-time PCR (15).
The clonal relationship of the isolates was evaluated by pulsed-ﬁeld gel
electrophoresis (PFGE). Total DNA from K. pneumoniae isolates and
Escherichia coli isolates was digested by using the XbaI enzyme (New Eng-
land BioLabs, Ipswich, MA, USA). The generated fragments were sepa-
rated by PFGE using a CHEF-DR III System (Bio-Rad), followed by mul-
tilocus sequence typing (MLST) (16) for one strain of each different PFGE
proﬁle. Sequence types (STs) were assigned using the databases (http:
//mlst.warwick.ac.uk/mlst/dbs/Ecoli/ and http://bigsdb.web.pasteur.fr
/klebsiella/klebsiella.html) for E. coli isolates and for K. pneumoniae iso-
lates, respectively. DNAs of plasmids harboring the blaOXA-181 gene were
extracted using the Kieser extraction method (17), electroporated into E.
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coli TOP10, and selected on LB agar plates supplemented with temocillin
(50 g/ml), which is selective for OXA-48-like -lactamase producers.
Plasmid sizes were evaluated by agarose gel electrophoresis using E. coli
NCTC50192 harboring four plasmids of 154, 66, 48, and 7 kb as plasmid
size markers. Plasmids carrying blaOXA-181 were characterized by PCR-
based replicon typing (PBRT) as described previously (18) by including
primers speciﬁc for IncX3-type plasmid backbones (IncX3 Fw, 5=-GAG
GCT TAT CGT GAA GAC AG-3=; IncX3 Rv, 5=-GAA CGA CTT TGT
CAA ACT CC-3=) and by restriction fragment length polymorphism
(RFLP) using restriction enzymes PvuII and HindIII, respectively. The
genetic environment of the blaOXA-181 genewas investigated by PCRmap-
ping with primers speciﬁc for insertion sequence ISEcp1, ISKpn19, or
IS3000, as previously described (6, 19), since previous studies showed they
might be located upstream of blaOXA-181.
Conjugation experiments. Mating-out assays were performed using
the azide-resistant E. coli J53 as the recipient. E. coli J53 and blaOXA-181-
carrying donors were separately inoculated overnight into LB broth and
incubated. The samples were then mixed at a ratio of 10:1 (donor/recipi-
ent) for 5 h and plated onto LB agar plates supplemented with temocillin
(50 g/ml) and sodium azide (100 g/ml). Susceptibility testing was per-
formed for all E. coli transconjugants, and positivity for blaOXA-181 was
checked by PCR.
Ethical approval. The protocol was approved by the institutional re-
view board of the hospital. Informed consent was obtained from the
guardians of the children after a verbal presentation of the purpose,
method, and design of the study.
RESULTS
All the patients were children from 3 months to 13 years old. They
were visiting the hospital for several reasons, either for treating
infections (pneumonia, peritonitis, malaria, and hepatitis) or for
surgery, tumors, leukemia, malnutrition, or renal failure. Limited
data in relation to antimicrobial therapy were available; the only
important issue was that penicillins and broad-spectrum cephalo-
sporins are quite often used in the hospital, but none of the chil-
dren had previously received carbapenems.
From the 157 patients, a total of 57 imipenem-nonsusceptible
and carbapenemase-producing enterobacterial isolates were iso-
lated (Table 1). They were recovered from a total of 48 patients; 9
patients were colonized with two different carbapenemase pro-
ducers. Out of the 57 community patients screened, only a single
carbapenemase producer was recovered, while 42 out of the 100
hospitalized patients were colonized by at least one carbapen-
emase-producing isolate.
Among the 57 carbapenemase-producing isolates, 50 were
found positive for the blaOXA-181 gene and 7 were positive for the
blaNDM-1 gene. None of the isolates coproduced two carbapen-
emases. Among the blaOXA-181-positive enterobacterial isolates, 25
E. coli isolates, 24 K. pneumoniae isolates, and a single Enterobacter
cloacae isolate were identiﬁed. The seven blaNDM-1 producers were
E. coli (n 4),K. pneumoniae (n 1),Providencia stuartii (n 1),
and Providencia rettgeri (n  1). Moreover, six out of the seven
blaNDM-1-positive isolates coharbored the rmtB or rmtH 16S
rRNA methyltransferase gene (Table 1). No isolate was positive
for the mcr-1 gene.
Notably, the majority of the isolates belonging to either the E.
coli or K. pneumoniae species exhibited low carbapenem MIC val-
ues, in particular for imipenem, with most isolates showing MIC
values of 0.5 or 1 g/ml.
The majority of the OXA-181-producing E. coli isolates (64%)
did not coproduce any ESBL and remained susceptible to broad-
spectrum cephalosporins, whereas almost all the K. pneumoniae
isolates (96%) were ESBL producers (Table 1).
Mating-out assays followed by plasmid analysis revealed four
different-size plasmids (ca. 30 kb, 64 kb, 70 kb, and 150 kb)
carrying the blaOXA-181 gene (Table 1). E. coli transconjugants har-
boring the 30-kb plasmid showed slightly higher MICs of carbap-
enems than the other transconjugants (4- and 2-fold-increased
MICs for imipenem and meropenem, respectively), suggesting
that the corresponding plasmid type could likely be present at
higher copy numbers and therefore could be enhancing the ex-
pression of the carbapenemase gene. Notably, although no ad-
ditional -lactamase gene was identiﬁed on the other two plas-
mid scaffolds, PCR ampliﬁcation showed that the 150-kb
plasmid bearing the blaOXA-181 gene coharbored the blaTEM-1
and blaCTX-M-15 -lactamase genes.
PCR mapping performed on all the positive isolates revealed
that a remnant of the ISEcp1 element was located upstream of the
blaOXA-181 gene, as previously reported on the IncX3-type plasmid
pOXA-181 from a Chinese E. coli isolate (20), with ISEcp1 being
truncated by the insertion of IS3000. Downstream of blaOXA-181,
and similar to what was observed on pOXA-181, ISKpn19 was
identiﬁed. Further downstream, the qnrS1 gene, encoding resis-
tance to quinolones and found on pOXA-181, was identiﬁed.
Overall, the same structure as that identiﬁed on pOXA-181 was
detected.
The mating-out assays were successful for all the carbapen-
emase-producing isolates as donors, except for a single blaOXA-181-
positive K. pneumoniae isolate (Table 1). PBRT analysis showed
that all the different-size plasmids carrying the blaOXA-181 gene
belonged to the same IncX3 group, and RFLP conﬁrmed that they
shared a common scaffold structure, with similar-size bands (data
not shown). The blaNDM-1 gene was identiﬁed on an IncFIA-type
plasmid for three E. coli isolates and on an IncA/C-type plasmid
for a single P. rettgeri isolate. PFGE and MLST analyses identiﬁed
nine different E. coli clones and 10 different K. pneumoniae clones
(Table 1).
DISCUSSION
Here, we report a high rate of recovery of carbapenemase-produc-
ing enterobacterial isolates from children in Angola and an im-
portant dissemination of the blaOXA-181 carbapenemase gene,
which might be considered endemic in that geographical area,
through the diffusion of conjugative plasmids. Indeed, 27.4% of
the screened individuals were found positive for carbapenemases,
and 88%of those carbapenemase-producing isolates harbored the
blaOXA-181 gene. This is particularly noteworthy considering that
none of the patients had received any current or past carbapenem-
based antimicrobial therapy.
The occurrence of NDM-1-producing isolates is also notewor-
thy, since the identiﬁcation of NDM-1 producers in Tunisia,
Morocco, Algeria, and South Africa shows that this carbapen-
emase, known to be widespread in the Indian subcontinent, may
also be widespread in Africa.
The rare association of the blaOXA-181 gene with an ESBL-
encoding gene in the E. coli isolates contrasts with the frequent
associations observed among blaOXA-48-positive K. pneumoniae
isolates, in particular with the blaCTX-M-15 ESBL gene. This further
underlines the fact that the blaOXA-48 and blaOXA-181 genes, al-









According to our data, the high rate of OXA-181 producers in
Luanda results from the spread of some predominant E. coli and
K. pneumoniae clones, but also from the dissemination of a self-
conjugative IncX3-type plasmid among different enterobacterial
isolates.
The plasmids harboring the blaOXA-181 gene were different in
size; nevertheless, they all shared the same backbone. It might be
hypothesized that they derive from a common IncX3 conjugative
plasmid. Notably, although all blaOXA-181-positive plasmids co-
harbored the qnrS1 gene conferring reduced susceptibility to
TABLE 1 Genetic features associated with the carbapenemase-producing isolates











E1 E. coli OXA-181, QnrS 64 IncX3 A1 ST5692 Acute care CIP 1 0.5 0.19
E2 E. coli OXA-181, CTX-M-15, QnrS 64 IncX3 A2 ST5692 Acute care CAZ-CIP 0.5 0.25 64
E3 E. coli OXA-181, QnrS 64 IncX3 A2 ST5692 Special care CIP 1 0.5 0.19
E4 E. coli OXA-181, QnrS 64 IncX3 A2 ST5692 Special care CIP 0.5 0.25 0.19
E5 E. coli OXA-181, QnrS 64 IncX3 A2 ST5692 Pediatrics CIP 0.5 0.25 0.19
E6 E. coli OXA-181, QnrS 64 IncX3 B3 ST38 Pediatrics CIP 1 0.5 0.19
E7 E. coli OXA-181, QnrS 64 IncX3 C ST3258 Surgery CIP 1 0.25 0.19
E8 E. coli OXA-181, CTX-M-15, QnrS 64 IncX3 D ST361 Pneumology CAZ-CIP-GEN-KAN-TOB 1 0.5 4
E9 E. coli OXA-181, CTX-M-15, QnrS 64 IncX3 F ST361 Special care CAZ-CIP 0.5 0.25 2
E10 E. coli OXA-181, QnrS 64 IncX3 G ST5692 Special care CIP 1 0.25 0.19
E11 E. coli OXA-181, CTX-M-15, QnrS 64 IncX3 H ST3268 Ambulatory CAZ-CIP 1 1 16
E12 E. coli OXA-181, CTX-M-15, QnrS 64 IncX3 I ST167 Pediatrics CAZ-CIP-KAN-TOB 0.5 0.25 128
E13 E. coli OXA-181, CTX-M-15, QnrS 64 IncX3 J ST5703 Pediatrics CAZ-CIP-KAN-TOB-GEN 1 0.5 32
E14 E. coli OXA-181, CTX-M-15, QnrS 30 IncX3 A1 ST5692 Acute care CAZ-CIP-TOB 0.5 0.5 256
E15 E. coli OXA-181, QnrS 30 IncX3 A1 ST5692 Surgery CIP 0.5 0.25 0.19
E16 E. coli OXA-181, QnrS 30 IncX3 A1 ST5692 Pneumology CIP 0.5 0.25 0.19
E17 E. coli OXA-181, QnrS 30 IncX3 A1 ST5692 Special care CIP 0.5 0.25 0.19
E18 E. coli OXA-181, QnrS 30 IncX3 A1 ST5692 Special care CIP 1 0.25 0.19
E19 E. coli OXA-181, QnrS 30 IncX3 A1 ST5692 Special care CIP 1 0.25 0.19
E20 E. coli OXA-181, QnrS 30 IncX3 A1 ST5692 Special care CIP 1 0.25 0.19
E21 E. coli OXA-181, QnrS 30 IncX3 B1 ST38 Pediatrics CIP 1 0.5 0.25
E22 E. coli OXA-181, QnrS 30 IncX3 B1 ST38 Pediatrics CIP 2 1 0.25
E23 E. coli OXA-181, CTX-M-15, QnrS 30 IncX3 B1 ST38 Pediatrics CAZ-CIP 2 1 128
E24 E. coli OXA-181, CTX-M-15, QnrS 30 IncX3 B2 ST38 Pediatrics CAZ-CIP 1 0.5 128
E25 E. coli OXA-181, QnrS 30 IncX3 E ST5692 Special care CIP 1 0.5 0.19
E26 E. coli NDM-1, CTX-M-15, RmtB 100 IncFIA ND ST5079 Pneumology CAZ-CIP-GEN-TOB-AMK 8 32 256
E27 E. coli NDM-1, CTX-M-15, RmtB 100 IncFIA ND ST5079 Pneumology CAZ-CIP-GEN-TOB-AMK 8 32 256
E28 E. coli NDM-1, CTX-M-15, RmtB 100 IncFIA ND ST5079 Pneumology CAZ-CIP-GEN-TOB-AMK 16 32 256
E29 E. coli NDM-1, CTX-M-15, RmtB 100 IncFIA ND ST5693 Pediatrics CAZ-CIP-GEN-TOB-AMK 8 8 256
K1 K. pneumoniae OXA-181, CTX-M-15, QnrS 150 IncX3 D ST1301 Pneumology CAZ-CIP-GEN-TOB 1 0.5 32
K2 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Acute care CAZ-CIP-GEN-TOB 1 1 128
K3 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Acute care CAZ-CIP-GEN-TOB 1 1 128
K4 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Acute care CAZ-CIP-GEN-TOB 0.5 0.5 128
K5 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Acute care CAZ-CIP-GEN-TOB 128 128 128
K6 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Acute care CAZ-CIP-GEN-TOB 128 128 128
K7 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Surgery CAZ-CIP-GEN-TOB 1 1 128
K8 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Surgery CAZ-CIP-GEN-TOB 0.5 0.5 128
K9 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Pediatrics CAZ-CIP-GEN-TOB 64 64 128
K10 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Pediatrics CAZ-CIP-GEN-TOB-AMK 64 64 128
K11 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Pediatrics CAZ-CIP-GEN-TOB 1 0.5 64
K12 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Pediatrics CAZ-CIP-GEN-TOB 4 8 128
K13 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 A ST2094 Pediatrics CAZ-CIP-GEN-TOB 16 8 128
K14 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 B ST2074 Surgery CAZ-CIP-GEN-TOB 0.5 0.5 2
K15 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 B ST2074 Surgery CAZ-CIP-GEN-TOB 0.5 0.5 128
K16 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 C ST2092 Surgery CAZ-CIP-GEN-TOB 1 1 128
K17 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 C ST2092 Surgery CAZ-CIP-GEN-TOB 0.5 0.5 128
K18 K. pneumoniae OXA-181, CTX-M-15, QnrS 30 IncX3 C ST34 Special care CAZ-CIP-GEN-TOB 1 1 16
K19 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 C ST231 Pediatrics CAZ-CIP-GEN-TOB 1 1 64
K20 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 E ST2093 Pneumology CAZ-CIP-TOB 1 1 128
K21 K. pneumoniae OXA-181, QnrS 64 IncX3 F ST2093 Pneumology CIP 0.5 0.5 0.19
K22 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 G ST2074 Pneumology CAZ-CIP-GEN-TOB 0.5 0.5 2
K23 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 H ST45 Pneumology CAZ-CIP-GEN-TOB 0.5 0.5 128
K24 K. pneumoniae OXA-181, CTX-M-15, QnrS 64 IncX3 I ST2094 Special care CAZ-CIP-GEN-TOB 128 128 128
K25 K. pneumoniae NDM-1, CTX-M-15 120 ST15 Treatment 1
room A
CAZ-CIP-GMI-TMN 8 4 256
Cl1 E. cloacae OXA-181, QnrS 64 IncX3 ND Pediatrics CIP 1 0.25 1
PR1 P. rettgeri NDM-1, CTX-M-15 100 ND ND Pediatrics CAZ-CIP-GEN-TOB 8 8 256
PS1 P. stuartii NDM-1, CTX-M-15 100 IncA/C ND Acute care CAZ-CIP-GEN-TOB 32 16 256
a Incompatibility group of the plasmid harboring the carbapenemase gene.
b Coresistances provided by the carbapenemase-encoding plasmids. AMK, amikacin; CAZ, ceftazidime; CIP, ciproﬂoxacin; GEN, gentamicin; KAN, kanamycin; TOB, tobramycin.








quinolones, no additional resistance markers were detected, with
the exception of a single 150-kb plasmid identiﬁed in only one
isolate that coharbored the blaTEM-1 and blaCTX-M-15 -lactamase
genes. In addition, this 150-kb plasmid was not self-conjugative,
in contrast to the other blaOXA-181-bearing plasmids identiﬁed.
This might be the consequence of the insertion of the two addi-
tional -lactamase genes in a region of the plasmid that is crucial
for its conjugative property.
Interestingly, the genetic environment of the blaOXA-181 gene
was identical to that identiﬁed recently by Liu et al. (20) in China,
also on an IncX3-type plasmid, with the blaOXA-181 gene ﬂanked
upstream by ISEcp1 truncated by IS3000 and downstream by
ISKpn19 followed by the qnrS1 gene. In other reports from differ-
ent parts of the world, the blaOXA-181 gene was identiﬁed on dif-
ferent plasmid backbones, including IncN and IncT plasmids (19,
21). IncX3-type plasmids harboring the blaOXA-181 gene seem to be
predominant in Asia. Indeed, a recent study showed that OXA-
181-producing isolates had been imported into Switzerland on
fresh vegetables originating from Asia (22).
Our data support the importance of active and continuous
surveillance of carbapenemase-producing Gram-negative bacte-
ria in health care facilities. They also show that not only Asia, but
also Africa, may act as an important reservoir of OXA-181.
Altogether, most isolates coharbored a high number of resis-
tance determinants that represent a major source of concern in
terms of public health.
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